LENZ Therapeutics grants 22,100 options to director

LENZ Therapeutics director George Jeffrey P. received a stock option grant covering 22,100 shares of common stock.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LENZ Therapeutics director George Jeffrey P. received a stock option grant covering 22,100 shares of common stock. The option has an exercise price of $6.63 per share and expires on June 15, 2036.

All 22,100 shares vest in a single tranche, provided he continues to serve as an Outside Director, on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Following this grant, he holds options for 22,100 shares directly.

Insider Trade Summary

Grant/Award: 22,100 shares

Grant/Award 1 txn

Insider George Jeffrey P.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,100	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,100 contracts (Direct)

Footnotes (1)

F1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Key Figures

Option grant size: 22,100 shares Exercise price: $6.63 per share Expiration date: June 15, 2036 +2 more

5 metrics

Option grant size 22,100 shares Stock option covering LENZ common stock

Exercise price $6.63 per share Stock option strike price

Expiration date June 15, 2036 Option term end date

Vesting date trigger June 15, 2027 or next annual meeting 100% vesting on earlier date if still Outside Director

Post-grant option holdings 22,100 shares Total options following transaction, held directly

Key Terms

Stock Option (right to buy), Outside Director, vesting, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Outside Director regulatory

"Subject to the Reporting Person continuing to be an Outside Director"

vesting financial

"one hundred percent (100%) of the shares subject to the option shall vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders regulatory

"on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LENZ (LENZ) director George Jeffrey P. report?

He reported receiving a stock option grant for 22,100 shares of LENZ common stock. The options were awarded as director compensation and give him the right to buy shares at a fixed exercise price if vesting conditions are met.

What is the exercise price of the new LENZ Therapeutics stock options?

The options have an exercise price of $6.63 per share. This means George Jeffrey P. can purchase LENZ common stock at $6.63 if he exercises the options once they vest and before they expire in 2036.

When do George Jeffrey P.’s LENZ stock options vest?

The options vest 100% on the earlier of June 15, 2027 or the date of LENZ’s next annual meeting of stockholders. Vesting requires that he continue serving as an Outside Director through the applicable vesting date under the company’s policy.

What is the expiration date of the LENZ stock options granted to the director?

The stock options expire on June 15, 2036. After that date, any unexercised options will lapse and can no longer be used to buy LENZ common shares, even if they were previously vested and exercisable.

How many LENZ shares can the director acquire through this option grant?

The grant covers 22,100 underlying shares of LENZ common stock. If all vesting conditions are satisfied and the options are fully exercised, he could acquire 22,100 shares at the fixed $6.63 exercise price per share.

Is this LENZ insider transaction a market purchase or a compensation grant?

It is a compensation-related grant, not a market purchase. The Form 4 describes the transaction with code A as a grant or award, providing stock options as part of his compensation for serving as an Outside Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/15/2026 - 08:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

George Jeffrey P.

(Last)

(First)

(Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH

CALIFORNIA

92075

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.63	06/15/2026		A		22,100		⁽¹⁾	06/15/2036	Common Stock	22,100	$0	22,100	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR